• 1
    Sauvageau C, Duval B, Gilca V, Lavoie F, Ouakki M. Human papilloma virus vaccine and cervical cancer screening acceptability among adults in Quebec, Canada. BMC Public Health. 2007; 7: 304.
  • 2
    Weinstock H, Berman S, Cates W Jr. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health. 2004; 36: 6-10.
  • 3
    Mariam A. Cervical cancer vaccines available in 2007. Drug Discov Today. 2005; 10: 949-950.
  • 4
    Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007; 56( RR-2): 1-24.
  • 5
    Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol. 2000; 151: 1158-1171.
  • 6
    Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007; 297: 813-819.
  • 7
    Eaton DK, Kann L, Kinchen S, et al. Youth risk behavior surveillance-United States, 2007. MMWR Surveill Summ. 2008; 57: 1-131.
  • 8
    Wulf D. In Their Own Right: Addressing the Sexual and Reproductive Health Needs of American Men. New York, NY: Alan Guttmacher Institute; 2002.
  • 9
    Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348: 518-527.
  • 10
    American Cancer Society. Cancer Facts & Figures, 2008. Atlanta, GA: American Cancer Society; 2008.
  • 11
    National Cancer Institute. National Cancer Institute Fact Sheet. 5.16th ed. The Pap Test: Questions and Answers. Bethesda, MD: National Cancer Institute; 2007.
  • 12
    Burchell AN, Winer RL, de Sanjose S, Franco EL. Epidemiology and transmission dynamics of genital HPV infection. Vaccine. 2006; 24( suppl 3): S52-S61.
  • 13
    Ault KA. Long-term efficacy of human papillomavirus vaccination. Gynecol Oncol. 2007; 107( 2 suppl 1): S27-S30.
  • 14
    Paavonen J, Lehtinen M. Introducing human papillomavirus vaccines—questions remain. Ann Med. 2008; 40: 162-166.
  • 15
    Ries LAG, Melbert D, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2003. Bethesda, MD: National Cancer Institute; 2006.
  • 16
    Watson M, Saraiya M, Ahmed F, et al. Using population-based cancer registry data to assess the burden of human papillomavirus-associated cancers in the United States: overview of methods. Cancer. 2008; 113( 10 suppl): 2841-2854.
  • 17
    Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006; 367: 1247-1255.
  • 18
    Koutsky LA, Harper DM. Current findings from prophylactic HPV vaccine trials. Vaccine. 2006; 24( suppl 3): S114-S121.
  • 19
    Centers for Disease Control. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2007; 56( RR-2): 1-26.
  • 20
    United States Food and Drug Administration. HPV (human papillomavirus) 2006. Available to: Accessed on June 18, 2008.
  • 21
    Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005; 6: 271-278.
  • 22
    Villa LL. Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine. Int J Infect Dis. 2007; 11( suppl 2): S17-S25.
  • 23
    Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006; 95: 1459-1466.
  • 24
    Saslow D, Castle PE, Cox JT, et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin. 2007; 57: 7-28.
  • 25
    Twombly R. U.S. girls to receive HPV vaccine but picture unclear on potential worldwide use, acceptance. J Natl Cancer Inst. 2006; 98: 1030-1032.
  • 26
    Hoffman J. Vaccinating boys for girls' sake? New York Times. February 24, 2008: ST1.
  • 27
    Merck Pharmaceutical Company. Gardasil, Merck's cervical cancer vaccine, demonstrated efficacy in preventing HPV-related disease in males in phase III study. Research & Development News, 2008.
  • 28
    Malouf MA, Hopkins PM, Singleton L, Chhajed PN, Plit ML, Glanville AR. Sexual health issues after lung transplantation: importance of cervical screening. J Heart Lung Transplant. 2004; 23: 894-897.
  • 29
    Rose B, Wilkins D, Li W, et al. Human papillomavirus in the oral cavity of patients with and without renal transplantation. Transplantation. 2006; 82: 570-573.
  • 30
    Courtney AE, Leonard N, O'Neill CJ, McNamee PT, Maxwell AP. The uptake of cervical cancer screening by renal transplant recipients. Nephrol Dial Transplant. 2009; 24: 647-652.
  • 31
    Vacher-Coponat H, Dussol B, Berland Y. Neoplastic disorders and organ transplantation [in French]. Rev Med Interne. 1999; 20: 992-1003.
  • 32
    Mass K, Quint EH, Punch MR, Merion RM. Gynecological and reproductive function after liver transplantation. Transplantation. 1996; 62: 476-479.
  • 33
    Seshadri L, George SS, Vasudevan B, Krishna S. Cervical intraepithelial neoplasia and human papilloma virus infection in renal transplant recipients. Indian J Cancer. 2001; 38: 92-95.
  • 34
    Hagensee ME, Cameron JE, Leigh JE, Clark RA. Human papillomavirus infection and disease in HIV-infected individuals. Am J Med Sci. 2004; 328: 57-63.
  • 35
    Fruchter RG, Maiman M, Arrastia CD, Matthews R, Gates EJ, Holcomb K. Is HIV infection a risk factor for advanced cervical cancer? J Acquir Immune Defic Syndr Hum Retrovirol. 1998; 18: 241-245.
  • 36
    Palefsky JM, Minkoff H, Kalish LA, et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst. 1999; 91: 226-236.
  • 37
    Di Stefano L, Coppola G, Moro S, Colageo E, Cellini A, Coletti G. Cervical-vaginal disease in HIV immunosuppressed patients: management and present screening programme. Eur J Gynaecol Oncol. 2006; 27: 267-270.
  • 38
    Parham GP, Sahasrabuddhe VV, Mwanahamuntu MH, et al. Prevalence and predictors of squamous intraepithelial lesions of the cervix in HIV-infected women in Lusaka, Zambia. Gynecol Oncol. 2006; 103: 1017-1022.
  • 39
    Sirivongrangson P, Bollen LJ, Chaovavanich A, et al. Screening HIV-infected women for cervical cancer in Thailand: findings from a demonstration project. Sex Transm Dis. 2007; 34: 104-107.
  • 40
    Bunin N, DiDomenico C, Guzikowski V. Hematopoietic stem cell transplantation. In: Schwartz CL, Hobbie WL, Constine LS, Ruccione KS, eds. Survivors of Childhood and Adolescent Cancer. Berlin, Germany: Springer; 2005: 271-282.
  • 41
    Socie G, Curtis RE, Deeg HJ, et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol. 2000; 18: 348-357.
  • 42
    Sasadeusz J, Kelly H, Szer J, Schwarer AP, Mitchell H, Grigg A. Abnormal cervical cytology in bone marrow transplant recipients. Bone Marrow Transplant. 2001; 28: 393-397.
  • 43
    Bhatia S, Louie AD, Bhatia R, et al. Solid cancers after bone marrow transplantation. J Clin Oncol. 2001; 19: 464-471.
  • 44
    Slivnick DJ, Ellis TM, Nawrocki JF, Fisher RI. The impact of Hodgkin's disease on the immune system. Semin Oncol. 1990; 17: 673-682.
  • 45
    Slivnick DJ, Nawrocki JF, Fisher RI. Immunology and cellular biology of Hodgkin's disease. Hematol Oncol Clin North Am. 1989; 3: 205-220.
  • 46
    Serraino D, Franceschi S, Talamini R, et al. Socio-economic indicators, infectious diseases and Hodgkin's disease. Int J Cancer. 1991; 47: 352-357.
  • 47
    Gross G, Ellinger K, Roussaki A, Fuchs PG, Peter HH, Pfister H. Epidermodysplasia verruciformis in a patient with Hodgkin's disease: characterization of a new papillomavirus type and interferon treatment. J Invest Dermatol. 1988; 91: 43-48.
  • 48
    Hennig EM, Nesland JM, Di Lonardo A, Venuti A. Multiple primary cancers and HPV infection: are they related? J Exp Clin Cancer Res. 1999; 18: 53-54.
  • 49
    Katz RL, Veanattukalathil S, Weiss KM. Human papillomavirus infection and neoplasia of the cervix and anogenital region in women with Hodgkin's disease. Acta Cytol. 1987; 31: 845-854.
  • 50
    Quayle AJ. The innate and early immune response to pathogen challenge in the female genital tract and the pivotal role of epithelial cells. J Reprod Immunol. 2002; 57: 61-79.
  • 51
    Fujimura M, Ostrow RS, Okagaki T. Implication of human papillomavirus in postirradiation dysplasia. Cancer. 1991; 68: 2181-2185.
  • 52
    Barzon L, Pizzighella S, Corti L, Mengoli C, Palu G. Vaginal dysplastic lesions in women with hysterectomy and receiving radiotherapy are linked to high-risk human papillomavirus. J Med Virol. 2002; 67: 401-405.
  • 53
    Seidman JD, Kumar D, Cosin JA, Winter WE III, Cargill C, Boice CR. Carcinomas of the female genital tract occurring after pelvic irradiation: a report of 15 cases. Int J Gynecol Pathol. 2006; 25: 293-297.
  • 54
    Yeazel MW, Oeffinger KC, Gurney JG, et al. The cancer screening practices of adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Cancer. 2004; 100: 631-640.
  • 55
    Castellino SM, Casillas J, Hudson MM, et al. Minority adult survivors of childhood cancer: a comparison of long-term outcomes, health care utilization, and health-related behaviors from the childhood cancer survivor study. J Clin Oncol. 2005; 23: 6499-6507.
  • 56
    Oeffinger KC, Mertens AC, Hudson MM, et al. Health care of young adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Ann Fam Med. 2004; 2: 61-70.
  • 57
    Zebrack BJ, Casillas J, Nohr L, Adams H, Zeltzer LK. Fertility issues for young adult survivors of childhood cancer. Psychooncology. 2004; 13: 689-699.
  • 58
    Moleski M. Neuropsychological, neuroanatomical, and neurophysiological consequences of CNS chemotherapy for acute lymphoblastic leukemia. Arch Clin Neuropsychol. 2000; 15: 603-630.
  • 59
    Mulhern RK, Fairclough D, Ochs J. A prospective comparison of neuropsychologic performance of children surviving leukemia who received 18-Gy, 24-Gy, or no cranial irradiation. J Clin Oncol. 1991; 9: 1348-1356.
  • 60
    Flory K, Molina BSG, Pelham WE Jr, Gnagy E, Smith B. Childhood ADHD predicts risky sexual behavior in young adulthood. J Clin Child Adolesc Psychol. 2006; 35: 571-577.
  • 61
    Barkley RA, Fischer M, Smallish L, Fletcher K. Young adult outcome of hyperactive children: adaptive functioning in major life activities. J Am Acad Child Adolesc Psychiatry. 2006; 45: 192-202.
  • 62
    Benard VB, Johnson CJ, Thompson TD, et al. Examining the association between socioeconomic status and potential human papillomavirus-associated cancers. Cancer. 2008; 113 ( 10 suppl): 2910-2918.
  • 63
    Parkin DM, Bray F. The burden of HPV-related cancers. Vaccine. 2006; 24( suppl 3): S3/11-S3/25.
  • 64
    Gurney JG, Krull KR, Kadan-Lottick N, et al. Social outcomes in the Childhood Cancer Survivor Study cohort. J Clin Oncol. 2009; 27: 2390-2395.
  • 65
    Kahn JA, Rosenthal SL, Jin Y, et al. Vaccine-type HPV infection and post-licensure attitudes about HPV vaccination in young women. J Adolesc Health. 2008; 42( 2 suppl 1): 28-29.
  • 66
    Kahn JA, Rosenthal SL, Jin Y, Huang B, Namakydoust A, Zimet GD. Rates of human papillomavirus vaccination, attitudes about vaccination, and human papillomavirus prevalence in young women. Obstet Gynecol. 2008; 111: 1103-1110.
  • 67
    Centers for Disease Control. Vaccination coverage among adolescents aged 13-17 years—United States, 2007. MMWR Morb Mortal Wkly Rep. 2008; 57: 1100-1103.
  • 68
    Boehner CW, Howe SR, Bernstein DI, Rosenthal SL. Viral sexually transmitted disease vaccine acceptability among college students. Sex Transm Dis. 2003; 30: 774-778.
  • 69
    Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Prev Med. 2007; 45: 107-114.
  • 70
    Davis K, Dickman ED, Ferris D, Dias JK. Human papillomavirus vaccine acceptability among parents of 10- to 15-year-old adolescents. J Low Genit Tract Dis. 2004; 8: 188-194.
  • 71
    Gerend MA, Lee SC, Shepherd JE. Predictors of human papillomavirus vaccination acceptability among underserved women. Sex Transm Dis. 2007; 34: 468-471.
  • 72
    Ziv A, Boulet JR, Slap GB. Utilization of physician offices by adolescents in the United States. Pediatrics. 1999; 104( 1 pt 1): 35-42.
  • 73
    Zimet GD, Mays RM, Winston Y, Kee R, Dickes J, Su L. Acceptability of human papillomavirus immunization. J Womens Health Gend Based Med. 2000; 9: 47-50.
  • 74
    Kahn JA, Zimet GD, Bernstein DI, et al. Pediatricians” intention to administer human papillomavirus vaccine: the role of practice characteristics, knowledge, and attitudes. J Adolesc Health. 2005; 37: 502-510.
  • 75
    Kahn JA, Rosenthal SL, Tissot AM, Bernstein DI, Wetzel C, Zimet GD. Factors influencing pediatricians” intention to recommend human papillomavirus vaccines. Ambul Pediatr. 2007; 7: 367-373.
  • 76
    Daley MF, Liddon N, Crane LA, et al. A national survey of pediatrician knowledge and attitudes regarding human papillomavirus vaccination. Pediatrics. 2006; 118: 2280-2289.
  • 77
    Marlow LA, Waller J, Wardle J. Parental attitudes to pre-pubertal HPV vaccination. Vaccine. 2007; 25: 1945-1952.
  • 78
    Dempsey AF, Zimet GD, Davis RL, Koutsky L. Factors that are associated with parental acceptance of human papillomavirus vaccines: a randomized intervention study of written information about HPV. Pediatrics. 2006; 117: 1486-1493.
  • 79
    Mulhern RK, Tyc VL, Phipps S, et al. Health-related behaviors of survivors of childhood cancer. Med Pediatr Oncol. 1995; 25: 159-165.
  • 80
    Weinberg A, Song LY, Handelsman E, et al. Safety and immunogenicity of a quadrivalent vaccine to prevent human papilloma virus infection in HIV-infected children: IMPAACT P1047. Paper presented at: 15th Conference on Retroviruses and Opportunistic Infections, February 3-6, 2008, Boston, Massachusetts.